ImmuCell Corporation Revenue for the Trailing 12 Months (TTM) ending March 31, 2023: USD 16.01 M

ImmuCell Corporation Revenue is USD 16.01 M for the Trailing 12 Months (TTM) ending March 31, 2023, a -24.23% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • ImmuCell Corporation Revenue for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 21.14 M.
  • ImmuCell Corporation Revenue for the Trailing 12 Months (TTM) ending March 31, 2019 was USD 12.52 M.
Key Data
Date Revenue Revenue Gross Profit Operating Income